[A clinical trial of triclabendazole in the treatment of human paragonimiasis skrjabini].

Abstract

OBJECTIVE:

To observe the therapeutic effect of triclabendazole in patients with paragonimiasis skrjabini.

METHODS:

Four patients were treated with triclabendazole at dosage of 10 mg/kg bid for 3 days and were followed up for 6-10 months. The clinical symptoms, chest X-ray, hemogram and liver function tests were observed before and after treatment.

RESULTS:

Migratory subcutaneous nodules in three patients all disappeared. Small amount of pleural effusion were absorbed in two patients. Severe headache subsided in a patient with cerebral lesion. MRI showed a bean-sized calcified spot in the right frontal region. Chest X-ray in 2 patients showed that pulmonary lesions were markedly absorbed and disappeared. There was no adverse effect of the drug.

CONCLUSION:

Triclabendazole has marked therapeutic effect on paragonimiasis skrjabini. It is safe in administration and well tolerated.

• Authors: P Hu, Y H Liu
• Journal: Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases (Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi) Vol. 19 Issue 5 Pg. 305-7 ( 2001) ISSN: 1000-7423 [Print] China
• PMID: 12572050 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Anthelmintics
• Benzimidazoles
• Triclabendazole

Topics

• Adolescent
• Adult
• Anthelmintics (therapeutic use)
• Benzimidazoles (therapeutic use)
• Child
• Female
• Follow-Up Studies
• Humans
• Male
• Paragonimiasis (drug therapy)
• Treatment Outcome
• Triclabendazole